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Stefan O. Ciurea, Borje S. AnderssonThe development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic
stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route
to achieve 100% bioavailability translated into improved control over drug administration, with increased
safety and reliability of generating therapeutic Bu levels, maximizing antileukemic efficacy. Bu-nucleoside an-
alog-based conditioning chemotherapy, thus far represented by fludarabine (Flu), is becoming the condition-
ing chemotherapy regimen of choice for patients with acute myelogenous leukemia (AML) at many transplant
centers. The use of busulfan Bu-based conditioning is extending rapidly also to hematopoietic stem cell trans-
plantation (HSCT) for lymphoid malignancies, genetic diseases, and umbilical cord blood transplantation.
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plantationINTRODUCTION (AA) model. These pioneer investigators combined oralThebifunctionalDNAalkylating agentBusulfan (Bu)
is now widely used as an alternative to total body irradia-
tion (TBI) in conditioning therapy for hematopoietic
stem cell transplantation (HSCT). However, initially,
oral Bu was used as a palliative treatment of chronic mye-
logenous leukemia (CML) and other myeloproliferative
disorders since the 1950s [1]. Several sulfonic-acid ester
derivatives had been identified as having potent antitumor
activity and being inhibitory of normal hematopoiesis.
One suchcompound,1,4-dimethanesulphonyloxybutane,
(Myleran, Bu), showed intense suppressive properties on
myelogenous cell proliferation and, ‘‘compared with X-
rays, it did not appreciably depress lymphocyte formation
at a dose which causes a 50% or more decrease in the
number of (circulating) neutrophils’’ [1].The authors per-
ceived a relative lack of adverse effects that allowed the
morewidespreaduse ofBu inpatientswithmyeloprolifer-
ative disorders,mainlyCML [1,2]. Later on, the use of Bu
wasgradually replaced frompalliative treatmentofmyelo-
proliferative diseases to pretransplant conditioning. This
emerged from the experience of Santos and Tutschka
[3], who translated to humans the potent myeloablative
effect of Bu observed in their murine aplastic anemiaUniversity of Texas M.D. Anderson Cancer Center,
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6/j.bbmt.2008.12.489Bu with cyclophosphamide (Cy), or Bu/Cy, to use it as
conditioning therapy for allogeneic HSCT in patients
with acute myelogenous leukemia (AML) [4]. Oral Bu/
Cy was quickly recognized as an effective pretransplant
regimen for a wide variety of hematologic malignancies
and nonmalignant disorders, providing a desired alterna-
tive to the standard regimen of TBI and Cy (TBI/Cy). A
slightly revised regimen (oral Bu/Cy2) remains a standard
conditioning regimen for HSCT [5].
Lately, however, myeloablative as well as pretrans-
plant reduced-intensity conditioning (RIC) with Bu in
combination with the nuceloside analog fludarabine
(Bu/Flu), is gradually replacing Bu/Cy and TBI/Cy as
the preferred conditioning regimens for patients with
myelogenous malignancies. Bu, in combination with
melphalan (Bu/Mel), is another promising condition-
ing regimen for both myelogenous and lymphoid
malignancies. As we look forward to the future, nucleo-
side analogs of later generation like clofarabine, drugs
with similar immunosuppressive capabilities as Flu,
but with greatly enhanced antileukemic properties,
are likely to complement Flu in combination with intra-
venous (i.v.) Bu.Moreover,we envision an i.v. Bu-nucle-
oside analog platform to safely deliver other agents
including chemotherapeutic drugs, immunomod-
ulatory, and cellular therapies added pre- and/or
posttransplant to further enhance the efficacy of prepar-
ative regimens and increase the benefit of HSCT.CLINICAL EXPERIENCE, THERAPEUTIC
RESULTS, AND TOXICITY
It has been more then 30 years since Thomas and
colleagues [6] published their results on 100 patients523
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ciple paper, demonstrating that stem cell transplanta-
tion (SCT) is not only feasible, but may be curative
for acute leukemia. Moreover, this group established
the use of TBI/Cy as a conditioning regimen for such
patients, using Cy at 50 mg/kg daily for 4 days in addi-
tion to 10GyTBI. Unfortunately, the price for this ap-
proach was a treatment-related mortality (TRM) in
excess of 50%, signaling a need for improved safety of
the procedure [6]. About the same time, Bleyer et al.
[7] reported a successful transplant after combination
chemotherapy without TBI, demonstrating that TBI
is not mandatory for a successful outcome of HSCT.
The use of TBI has subsequently become associated
with a variety of immediate and long-term posttrans-
plant complications, including retarded intellectual de-
velopment and stunted growth in children, as well as
secondary malignancies, cataracts, and endocrine dys-
function, all of which support the development of alter-
native conditioning regimens for HSCT [8-10].
Santos et al. [4] reported, in 1983, on the replace-
ment of TBI with high doses of Bu. Bu, as the
antileukemic agent, in combination with Cy as an
immunosuppressive adjunct, proved to be an effective
conditioning regimen [4]. This group treated 51
patients with AML with Bu at 1 mg/kg orally every 6
hours for 16 doses followed byCy at 50mg/kg i.v. daily
for 4 days (Bu/Cy) [4]. An every 6-hour schedule was
arbitrarily chosen because Bu tablets were highly irri-
tating to the gastric mucosa, thus emetogenic, and pa-
tients were required to take a large number of tablets to
achieve the desired Bu systemic exposure (SE). These
investigators showed a clear stratification of outcomes
based on disease status at transplant: 44% of the
patients in first complete remission (CR1) achieved
stable long-term remission, compared with 0% for
patients with more advanced disease [4]. Overall, grade
ii-iv acute graft-versus-host disease (aGVHD) devel-
oped in 44% of patients and chronic GVHD
(cGVHD) in 22%. Clinically significant hepatic fail-
ure, veno-occlusive disease (HVOD), occurred in 3
patients [4]. These results again demonstrated that
TBI can be replaced in the pretransplant conditioning
for acute leukemia patients. However, a TRM rate of
73% was reported in this study. Because of this high
treatment-related toxicity (including, but not limited
to HVOD), Tutschka and colleagues [5] revised the
preparative regimen for patients with leukemia. This
group reduced the Cy dose from 200 mg/kg to 120
mg/kg (60 mg/kg daily administered over 2 days),
but used the same dose of Bu (1 mg/kg every 6 hours
for 16 doses) [5]. Fifty patients with leukemia (AML,
acute lymphoblastic leukemia [ALL], and CML)
were treated with this modified regimen with remark-
able results; neutrophil engraftment was achieved in
96% of patients after a median of 13 days. No one
had severe mucositis, only 1 patient developed clini-cally significant, but reversible, HVOD, and the actu-
arial 3-year overall survival (OS) was 65% [5]. A
surprisingly low incidence of infectious complications,
coupled with a low incidence of GVHD, was also
noted [5]. This study showed that the Cy dose reduc-
tion did not compromise the antileukemic activity,
but significantly reduced the toxicity of the condition-
ing regimen. These results compared favorably with
TBI/Cy, especially for patients with CML, established
a new standard in conditioning chemotherapy for
HSCT for patients with leukemia, and prompted
larger scale comparisons between the Bu/Cy2 regimen
and the more established TBI/Cy regimen.
Investigators at the Fred Hutchinson Cancer
Research Center (FHCRC) performed a study com-
paring oral Bu/Cy2 with TBI/Cy as conditioning for
CML patients receiving allogeneic HSCT [11], and
3 other multiinstitutional, randomized studies com-
pared Bu/Cy2 with TBI/Cy as conditioning regimen
in myelogenous leukemias [12-14]. In an additional
single-institution study, oral Bu/Cy2 was compared
with TBI-Etoposide [15]. A meta-analysis [16], and
a long-term follow-up study of the first 4 studies
revealed similar results; Socie et al. [17] reported the
results of 488 patients, 316 with CML and 172 with
AML, treated with Bu/Cy2 or TBI/Cy after a median
follow-up of 7 years. All patients received either Bu 1
mg/kg by mouth every 6 hours for 4 days, or 10 Gy
TBI plus the same dose of Cy, 60 mg/kg/day for 2
days. There was no difference in projected 10-year
OS between patients treated with Bu/Cy2 and TBI/
Cy (65% versus 63%, respectively) in CML, whereas
a numeric, but statistically nonsignificant, difference
in survival was noted in AML patients, whose pro-
jected 10-year OS was 51% and 63% after Bu/Cy2
andTBI/Cy, respectively. Further, there was no differ-
ence in extensive cGVHD between the 2 groups for ei-
ther disease type. The frequency of HVOD was not
reported. The incidence of cataracts was significantly
higher in CML patients after TBI/Cy, and this com-
plication was also associated with cGVHD. The only
other difference was a slightly higher incidence of
(permanent) alopecia after
Bu-based therapy. The overwhelming majority of
patients in these studies were adults, however, and
the delayed growth and retarded intellectual develop-
ment, which remain major concerns with TBI-based
conditioning in children, could not be assessed. The
CML study at the FHCRC showed similar outcomes
as the European studies. None of these studies, unfor-
tunately, had a long enough follow-up to address the
development of secondary malignancies, which needs
more than a decade of lead time after radiation ther-
apy, and which is being increasingly recognized after
the use of involved-field (mantle) radiation therapy
for Hodgkin lymphoma (HL) [18-20]. Moreover,
a dramatic increase in the incidence of secondary solid
Biol Blood Marrow Transplant 15:523-536, 2009 525Busulfan in HSCTtumors has also been observed after autologous trans-
plant with TBI/Cy for non-Hodgkin lymphoma
(NHL) [21], confirming data from the treatment of
Hodgkindisease,which suggested that a combined che-
motherapy-radiation program may have an increased
incidence of malignancies than the chemotherapy-
only approach (with alkylating agents) [8-10,22,23].
Although overall there was no major difference in
outcomes after TBI- and Bu-based conditioning ther-
apy in these large studies, Bu/Cy2 slowly became
accepted as a new standard conditioning regimen for
myeloid leukemias and caused a shifting trend away
from TBI in pretransplant therapy for most myeloge-
nous disorders, an expected result considering its ease
of administration and the lack of need for a TBI facility
when using chemotherapy alone.
The toxicity from virtually any ablative preparative
regimen has been associated with development of
HVOD [24-26]. Accordingly, HVOD and/or hepa-
torenal failure have been of concern with oral Bu
administration in combination with Cy, and was com-
monly considered a ‘‘trademark’’ toxicity associated
with high-dose Bu (both the original Bu/Cy and
Bu/Cy2 regimen) [27-30]. Additionally, oral Bu is as-
sociated with a hepatic first-pass extraction effect
that can result in locally high Bu concentrations in
the portal-hepatic venous system, which conceivably
may contribute to the development of HVOD [31].
However, in addition to Bu, Cy is clearly also hepato-
toxic. The contributions of other alkylating agents to
the emergence of HVOD, such as Cy or thiotepa
(TT), have been illustrated by several investigators
[32-34]. Briefly, Hassan et al. [32] showed that the
time interval between the last Bu dose and the first
Cy dose in Bu/Cy2 is of importance for the develop-
ment of HVOD. If this interval was .24 hours, the
risk of HVOD was significantly lower than if it were
\12 hours [32]. McDonald and coworkers [33] dem-
onstrated a highly significant association between the
blood levels of certain Cy metabolites and VOD after
TBI/Cy. Finally, Przepiorka and coworkers [34] dem-
onstrated that replacing 25% to 30% of the Bu dose in
Bu/Cy2withTT (TT-Bu/Cy) resulted in aHVOD in-
cidence in excess of 30%, or at least as high as that re-
ported in the literature with the standard Bu/Cy2 in
patients transplanted for high-risk hematologic malig-
nancies. Together, these data illustrate that the
development of HVOD is likely multifactorial. The
findings ofMcDonald et al. [33] suggest that interindi-
vidual differences in metabolic drug handling are of
importance for development of HVOD, with Cy being
a probable contributor to the overall risk. This risk
should be expected to further increase with the use of
2 or more alkylating agents that utilize hepatic GSH
stores for their detoxification. When such drugs
are combined in close time proximity they jointly
contribute to the depletion of hepatic GSH, resultingin an exacerbated risk for serious hepatic injury,
HVOD, also known as sinusoidal obstruction syn-
drome (SOS).
In addition to HVOD, neurotoxicity was associ-
ated with Bu in animals [35]. Convulsions in a patient
receiving Bu were first reported by Marcus and
Goldman [36]. The incidence of neurotoxicity after
Bu-based conditioning therapy was subsequently
estimated to be up to 10% in adults [37], and approx-
imately 7% in children [38]. Vassal et al. [39] reported
that higher doses (.600/m2 or 16 mg/kg) were associ-
ated with an increased probability of neurotoxic man-
ifestations. Such adverse events have been correlated
with the capacity of Bu to cross the blood-brain barrier
and is manifested primarily as generalized seizures. A
limited degree of plasma protein binding allows Bu,
unlike other lipophilic alkylating agents like Mel, to
easily cross the blood-brain barrier and achieve levels
in CSF that are similar to those in plasma [39,40]. An
altered blood-brain barrier may further increase the
susceptibility to Bu-associated neurotoxicity. Seizures
are more common in older patients, and appear to be
dose dependent both in adults and children
[38,40,41]. In adults, seizures typically occur in the
third or fourth day of Bu administration, probably as
a result of drug accumulation [36,40-44]. Even without
overt seizure activity EEG abnormalities can occur in
up to 60% of patients [42]. Various anticonvulsant
medications have been used for seizure prophylaxis in-
cluding phenobarbital sodium, benzodiazepines (clo-
nazepam, lorazepam), and phenytoin [41,42,45-47].
Phenytoin has been widely used for seizure prophylaxis
in patients receiving Bu as part of the conditioning reg-
imen because of its nonsedating properties. An i.v.
loading dose is commonly administered to achieve
a therapeutic level (10-20 ng/mL), thereby avoiding
the delay in achieving a therapeutic level, which is
commonly seen with oral phenytoin. Hassan and col-
leagues [48] showed that phenytoin used as prophylac-
tic anticonvulsant caused a higher clearance of oral Bu
as opposed to when diazepam was used and, therefore,
suggested that drugs without microsomal enzyme-in-
ducing properties should be used for Bu seizure pro-
phylaxis. Benzodiazepines have since been employed
for prophylaxis by numerous investigators [46-48].
However, despite their use, occasional patients still de-
velop seizures with benzodiazepine prophylaxis [49].
The sedation associated with benzodiazepines may
be considered less desirable by some patients, and
newer anticonvulsants like leviracetam, which does
not interfere with the hepatic microsomal cytochrome
P450 pathway, remain to be investigated for seizure
prophylaxis in this setting.
These clinical data and related concerns about oral
Bu toxicity formed the basis for our hypotheses that (1)
an i.v. Bu formulation might cause less stress to the
liver, because parenteral administration will alleviate
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circumvent the first-pass effect of oral drug, and (2)
combining Bu with an alternative immunosuppressive
agent without hepatic metabolism, that is, replacing
Cy with a nucleoside analog, should yield increased
safety of the conditioning therapy, because only 1 of
the 2 drugs is now dependent on hepatic glutathione
(GSH)-stores for its detoxification.
The practical limitations in using oral Bu relate
primarily to its unpredictable and erratic bioavailabil-
ity because of variable intestinal absorption. This
prompted the design of an i.v. Bu formulation to
achieve absolute dose assurance associated with its
controlled administration [50]. The pharmacokinetics
of i.v. Bu was evaluated in a phase I clinical trial per-
formed in 15 patients with hematologic malignancies
[51]. The new preparation was evaluated in combina-
tion with oral Bu and Cy. An i.v. Bu dose of 0.8 mg/
kg and a targeted area under the curve (AUC) of
1100-1200 mmol/L per min were identified as equiva-
lent to oral drug at an average of 1.0 mg/kg, and there-
fore considered for subsequent phase II study [51]. In
this study, the average bioavailability of oral Bu was
69%, ranging from\10% to virtually 100%. These
results were confirmed by the papers of Hassan et al.
[52], and Schuler et al. [53], who estimated the average
bioavailability of oral Bu to be in the order of 70% to
80%, using different parenteral reference formula-
tions. A phase II clinical trial was performed in 61 pa-
tients with advanced hematologic malignancies (75%
with active disease at transplant) treated with i.v. Bu
(0.8 mg/kg every 6 hours  16) followed by Cy (60
mg/kg i.v. daily  2) [54]. The regimen was very well
tolerated (day 100 TRM was\10%); however, 2 pa-
tients developed fatal HVOD, 1 of whom had a prior
HSCT. Eighty-six percent of the patients achieved
an AUC of 800-1500 mMol-min [54].
The combination of Cy with i.v. Bu administration
appeared safer compared with that of oral Bu. So far,
i.v. Bu/Cy2 has been compared with oral Bu/Cy2 in
5 retrospective studies, all showing superiority of i.v.
Bu/Cy2 with regard to the development of HVOD
and early TRM [55-59]. Kashyap, et al. [55] observed
a significantly lower incidence of HVOD in patients
with hematologic malignancies treated with i.v. com-
pared with oral Bu (33% versus 8%) and a significantly
lower day 100 TRM. In multivariate analysis, the use
of the oral formulation was the strongest predictor
of the development of HVOD. Similar results were
noted for patients with myelogenous diseases (leuke-
mias and myelodysplastic syndrome [MDS]) [56-58]
and lymphoid malignancies (NHL) [59]. Interestingly,
Aggarwal et al. [59] reported, that in 49 patients who
underwent autologous stem cell transplant for inter-
mediate and high-risk NHL with pharmacokinetic
monitoring (area under the curve [AUC] 1000-1500
mMol/min), the use of i.v. Bu yielded not only a reduc-tion in nonrelapse mortality from 28% to 3%, but
a significantly improved overall and progression-free
survival (PFS) were also noted with i.v. compared
with oral Bu. The latter findings were supported by
Dean and coworkers [60], who reported improved
outcomes of NHL patients undergoing auto-HSCT
using i.v. Bu/Cy2 compared with a reference group
that had received the oral formulation.
The introduction of i.v. Bu with Cy appeared to
improve the safety of the Bu/Cy2 regimen; however,
early regimen-related toxicity was still of concern.
It had become apparent through the work of
McDonald and coworkers [25,33] that Cy, used in
high doses in the pretransplant setting, contributed
to significant hepatotoxicity, regardless of whether
Bu is incorporated in the regimen. Thus, as the metab-
olites of Cy (especially o-carboxyethyl-phosphoramide
mustard) likely contribute to HVOD in the double al-
kylating Bu/Cy conditioning regimen, the risk for this
untoward effect could conceivably be decreased by
substituting Cy with an immunosuppressive agent
from a different class without hepatotoxicity [25,61].
Fl would fulfill these criteria; Flu is an antimetabolite
nucleotide inhibitor of DNA synthesis with powerful
immunosuppressive properties. It potentiates radiation-
and alkylator-induced cytotoxicity through inhibition
of DNA damage repair [62,63]. From these studies it
can be deduced that Flu most likely has a similar syn-
ergistic interaction with Bu. Flu was introduced in
HSCT by Terenzi and colleagues [64], concerned
about other adverse effects associated with high-dose
Cy, such as hemorrhagic cystitis, interstitial pneumo-
nia, and cardiotoxicity, rather then hepatotoxicity, as
they intended to use it in combination with TBI. Flu
was equally immunosuppressive to Cy in mice, and be-
cause of significantly less adverse effects, it was an ex-
cellent candidate for replacement of Cy in preparative
regimens for HSCT. Slavin and colleagues [65] subse-
quently reported on a reduced-intensity conditioning
(RIC) regimen using oral Bu and Flu (Bu/Flu) as pre-
parative regimen for 26 patients with hematologic
malignancies and nonmalignant disorders undergoing
matched sibling donor HSCT. This RIC regimen was
well tolerated; however, relapse remained a major
cause of treatment failure [66].
Bornhauser and colleagues [67] usedoral Bu in com-
bination with Flu (Flu 30 mg/m2 i.v. once daily for
4 days followed byBu 1mg/kg every 6 hours for another
4 days). The Bu dose was adjusted to target steady-state
plasma levels of 9006 100 ng/mL (approximately 1200-
1500 mMol-min). Fourty-two patients with MDS and
CML were treated. Engraftment was achieved in all
patients with very low day 100 regimen-related
mortality. Twelve patients (29%) died of relapsed
disease, whereas the 1-year TRM was 24% [67].
The long half-life of Flu allows once daily admin-
istration, and in combination with i.v. Bu has been
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plastic activity [68,69]. The combination of Flu with
Bu was developed to achieve effective myeloablation,
and optimize antileukemic activity and safety of the
conditioning therapy [68,69].
Russell and colleagues [68] initially reported on
a myeloablative conditioning regimen using i.v.
Bu-Flu and ATG in a convenient once-daily dosing.
Seventy patients with hematologic malignancies were
treated with a combination of Flu 50 mg/m2 on days
26 to 22 and i.v. Bu 3.2 mg/kg ideal body weight
(IBW) daily on days25 to22, and all patients received
antimyocyte glubulin (ATG), 4.5 mg/kg [68]. In a sec-
ond, disease-specific study, performed at the M.D.
Anderson Cancer Center (MDACC), Flu and i.v. Bu
were given once daily, with each dose of Bu following
Flu to achieve synergistic cytotoxicity and high intra-
cellular Bu concentrations [62,69]. Ninety-six patients
with AML/MDSwere treated in this study with a com-
bination of fludarabine 40 mg/m2 daily for 4 days
followed immediately by i.v. Bu 130 mg/m2 daily for
4 days (26 to 23). ATG was added only for matched
unrelated donor and 1 antigen mismatched sibling
donor-patients [69]. More than 97% of the patients
achieved primary engraftment in these 2 studies
[68,69]. Complete chimerism was recorded in 70%
by day 30, increased to 100% in 84% of patients by
day 100, with the rest having a stable mixed chimera
with a median of 98% donor cells. The 100 day treat-
ment-related mortality was\5%, and the incidence of
serious aGVHD (grade III-IV) was \10% in both
studies. cGVHDwas noted in 38% and 55% of the pa-
tients, respectively [68,69]. Overall, 34% of the AML
patients relapsed in the MDACC study [69], whereas
the relapse rates (21% and 26%) for patients with
AML treated in CR1 were similar in both reports.
Disease-free survival (DFS) and OS were 74% and
75%, and 88% and 81% (at 2 years for patients in
the first study and 1 year in the second study), respec-
tively, for patients transplanted in any CR. Pharmaco-
kinetic studies revealed that Bu was cleared in \24
hours without drug accumulation and with\20% in-
terdose variability in clearance and AUC. The median
calculated daily Bu AUC values were 4866 and 4980
uMol-min, respectively [68-70]. Stomatitis was the
most common toxicity (grade 2 occurring in more
than 50% of patients). The majority of patients in the
first study, and 18% and 9%, respectively, in the sec-
ond study, also had transient elevations of alanine ami-
notransferase (ALT) and conjugated bilirubin within 1
to 2weeks after transplant, without the development of
HVOD. Only 3 of 166 (1.8%) patients treated in these
2 trials developed clinically significant HVOD, 1 of
whom died. Neurotoxicity was also rare; 4% of pa-
tients developed a hand-foot syndrome in de Lima
and colleagues study [69], and 2 patients developed
seizures, 1 reported by Russell, et al [68] as havinga subtherapeutic phenytoin level and 1 at 6 weeks after
transplant likely related to tacrolimus. Interstitial
pneumonitis was not reported in either study.
These results suggested that i.v. Bu/Flu was effec-
tive and safe. Moreover, in a Bayesian comparison with
i.v. Bu/Cy, Andersson et al. [71] demonstrated that i.v.
Bu/Flu has very similar antileukemic activity to i.v. Bu/
Cy2 in AML/MDS. Although no head-to-head com-
parison with Bu/Cy2 exists, available retrospective
data comparing Bu/Flu with Bu/Cy2 strongly suggest
that, indeed, i.v. Bu/Flu is safe and at least as effective
as Bu/Cy2 for patients with myelogenous malignan-
cies undergoing HSCT [71,72]. Recent matched-
case data appear to challenge the latter when used
for a multitude of hematologic malignancies, at least
when ATG is routinely included as part of the condi-
tioning regimen to alleviate GVHD, and when given
in close proximity to the transplant to more effectively
remove T cells from the graft [73]. Thus, these authors
confirmed the superior safety of the i.v. Bu/Flu-ATG
regimen, yet claimed better antitumor activity of oral
Bu/Cy2 when used without ATG [73]. The addition
of ATG may have resulted in increased in vivo T cell
depletion and could explain the different results
between this study and the previous 2 manuscripts
[71-73]. A randomized comparison of i.v. Bu/Flu and
Bu/Cy2 could be necessary to resolve this conflict. Re-
gardless, the impressive safety profile is getting the re-
duced-toxicity i.v. Bu/Flu regimens adopted as the
new ‘‘standard of care’’ preparative regimen for mye-
loid diseases by many transplant centers around the
world.BU PHARMACOKINETICS, SYSTEMIC
EXPOSURE, AND THERAPEUTIC INTERVAL
The extreme variability in bioavailability and
pharmacokinetics (PK) of oral Bu led to important
discoveries of the relationship between PK and
clinical endpoints such as engraftment and toxicity
[27-30,38-40,74-76]. A large (retrospective) experi-
ence with the Bu/Cy preparative regimen in adults
established a Bu therapeutic window in the range
of 900 to 1500 mMol/min, surrogate numbers
representing the average AUC value after 1 of 16
doses in a typical every 6-hour BuCy regimen, or
a total course AUC of 14,400-24,000 uMol/min
[27-30,75,76].
Consequently, very low Bu AUC levels (below 900
mMol-min) have been correlated with graft failure and
disease recurrence [29,30], whereas high Bu systemic
exposure (Bu-SE) (above 1500 mMol/min) have been
associated with increased toxicity, especially hepatic
and neurologic toxicity [27-32,36,38-40,44,52]. In
particular, several studies concluded an association
between HVOD and an elevated Bu-SE, represented
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all investigators agree with this interpretation [77], and
indeed, the development of HVOD appears to be mul-
tifactorial. HVOD occurs with increased frequency
after previous hepatic irradiation [78], and/or the in-
clusion of other hepatotoxic chemotherapy (ie, alkylat-
ing agents), like Cy, whose hepatotoxic metabolites,
acrolein and phosphorodiamidic mustard, have a clear
etiologic role in the generation of this disease [33,79].
Furthermore, Johnson et al. [80] reported that various
isoenzymes of glutathione-S-transferase affect Bu me-
tabolism to various degrees. Carriers of GSTA1*B had
a 30% reduced Bu clearance and on average a 2.6-fold
higher Bu AUC compared with noncarriers [80].
Finally, a transient (reversible) elevation of liver func-
tion tests, predominantly after methotrexate adminis-
tration, has been noted in patients receiving i.v. Bu
without other signs of HVOD [68,69], suggesting
that a careful clinical evaluation and use of strict, stan-
dardized diagnostic criteria for HVOD (such as Jone’s
criteria) are important for establishing a diagnosis of
HVOD [24]. We previously reported that a signifi-
cantly higher rate of aGVHD, gastrointestinal, and
hepatic toxicity, is associated with excessive Bu-SE.
In contrast, posttransplant mortality showed a bimodal
distribution, being significantly increased with both
very high and low Bu-SE, thereby confirming the
presence of a therapeutic interval for i.v. Bu of approx-
imately 950-1520 mMol/min in the prototype i.v. Bu/
Cy2 regimen [81]. This therapeutic interval was the
only factor predictive of survival in CML patients
transplanted using the i.v. BuCy2 therapy. The avail-
ability of detailed pharmacokinetic information in
clinical Bu dosing has been reported to improve pa-
tient outcome when applied with both oral and i.v.
Bu, even though the erratic bioavailability of oral Bu
has put the value of therapeutic dose monitoring
into question [77]. A carefully controlled study at
the FHCRC by Deeg and colleagues [82] reported
clinical outcomes in 50 patients between the ages or
55 and 66 transplanted for MDS. The conditioning
regimens included TBI/Cy, Cy-fractionated TBI,
(oral) Bu/TBI and targeted (oral) Bu/Cy2. Sixteen pa-
tients received oral Bu targeted to average steady-state
plasma levels of 600-900 ng/mL (approximately
900-1350 mMol/min) and Cy. The cohort receiving
PK-targeted oral Bu with Cy had the lowest nonre-
lapse mortality (NRM) and best survival [82]. The
discrepancy in opinion about the predictive value of
oral Bu-derived PK parameters likely resides in the
up to 3-fold variability in dose-to-dose AUC in any
patient receiving oral drugs [83]. Therefore, to some-
what accurately estimate the total course AUC after
oral dosing, a minimum of 4 to 5 complete plasma
concentration profiles may be necessary after a typical
16-dose regimen [75,84]. This necessitates not only
in-house access to PK-laboratory services with thesame day turnaround PK reporting, but also requires
very dedicated staff to procure and analyze all samples
(an estimated 5-10 samples per dosing profile) that
have to be included in the analytic profile from indi-
vidual patients.
Although high variability of Bu-SE when com-
bined with Cy has been associated with adverse out-
comes in adults, such a relationship between Bu
exposure and HVOD has not been clearly established
in children [85]. Still, some investigators insist that
targeted Bu-SE, AUC, does improve outcomes in
pediatric patients, and have demonstrated a higher
engraftment rate and lower incidence of HVOD with
a consistently utilized therapeutic drug monitoring
(TDM) strategy [85-87]. Again, the application of
TDM in the setting of oral drug administration is
fraught with the extremely labor-intensive need for
serial complete PK dosing profiles after consecutive
Bu doses to provide reliable and reproducible data
[75,84]. This area potentially represents the most pro-
nounced advantage for a parenteral Bu formulation
with its minimal interdose variability in PK parameters
[70].
The retrospective confirmation of an association
between Bu-PK and clinical outcome after HSCT
formed an incentive for TDM, which was intro-
duced to reduce the highly variable Bu-SE, thereby
improving the safety of (oral) Bu-based high-dose
chemotherapy. However, when accuracy of dosing
and rapid onset of action is important, PK accuracy
is always superior for i.v. versus orally administered
drugs [88]. We postulated that a parenteral Bu for-
mulation would in itself provide an improved tool
for safe myeloablative conditioning therapy because
it circumvents both unpredictable intestinal absorp-
tion and the hepatic first-pass extraction [31]. It
also allows TDM to be implemented to further re-
duce interpatient variability because of differences
in metabolic drug clearance. Subsequently, precise
Bu delivery was confirmed to be even more impor-
tant than previously thought, not only in relation
to early regimen-related toxicity and the develop-
ment of aGVHD, but also in predicting the likeli-
hood of being alive beyond 1 year after HSCT
[81]. More recently, the i.v. Bu/Flu combinations
are promising to be safer overall than Bu with
Cy or other alkylating agents. It is conceivable,
that a therapeutic interval will exist for i.v. Bu in
combination with nucleoside analogs (Flu) as well.
Indeed, Geddes et al. [89] indicated that a Bu-
SE/AUC in excess of 6000 mMol/min daily, or a to-
tal course AUC in excess of 24,000 mMol/min, was
associated with inferior survival, but additional
work will be required to establish the exact bound-
aries of such an i.v. Bu therapeutic interval, when
delivered in combination with (a) nucleoside ana-
log(s).
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COMPARISONWITH THE ORAL DRUG
In (myeloablative) pretransplant chemotherapy
dosing accuracy is of major importance, and it is there-
fore always preferable to use parenteral drug formula-
tions [88]. The introduction of i.v. Bu allowed both
optimized safety and detailed PK assessments without
resorting to the extremely labor-intensive schedules
that are required for realistic PK-modeling with oral
Bu [75,84]. We and others proposed that parenteral
Bu would improve the safety of the conditioning regi-
men, as the 100% dose assurance of i.v. Bu guarantees
that therapeutic drug monitoring can be optimized. As
is the case with all PK assaying, however, reliable PK
information can only be acquired if attention is also
paid to a multitude of details including the infusion
(priming the tubing with drug, not saline, all the way
to the patient, infusion by controlled-rate pump, and
finally disconnecting all of the tubing and pump cas-
sette at the end of infusion without the use of ‘‘saline
chasers’’ to ‘‘clean the line from drug’’). Meticulous
recording of infusion and sampling times also has to
be exercised. Recently published studies have con-
firmed that the variability in PK parameters after i.v.
Bu dosing is significantly lower than that recorded
with the oral formulation [54,68-70]. In contrast, the
conclusion may be that use of the respective i.v. and
oral Bu formulations yield the same (major) variability
in PK parameters as those reported in the oral Bu
literature [90].
At least 3 different Bu solvent systems have been
utilized clinically [50,53,91,92] by independent inves-
tigators to estimate oral drug bioavailability by com-
paring the systemic exposure represented by AUC,
after a predetermined oral dose with that of an i.v. ref-
erence dose with 100% bioavailability, in the same
patients. All arrived to a similar conclusion, namely
that, in adults, the average bioavailability of oral Bu
is 70% to 80%, and, collectively, these reports un-
equivocally established that the i.v. Bu dose equivalent
of 1 mg/kg oral Bu would be 0.7-0.8 mg/kg [51-53].
The 0.8 mg/kg dose has subsequently been used in sev-
eral phase II studies of i.v. Bu [54,56-60,71].BU-BASED CONDITIONING THERAPY IN
PEDIATRIC TRANSPLANTATION
Concerns about delayed growth and retarded
intellectual development have been associated with
the use of TBI in children, and it influenced a gradual
shift to chemotherapy-only conditioning in pediatric
transplantation. Bu has frequently been included in
conditioning regimens used in pediatric HSCT since
the early 1980s when the Bu/Cy regimen was
introduced. Significant variability in Bu clearancewas demonstrated in children [38,39,75,84-86,93].
The apparent plasma clearance rates in younger chil-
dren can be up to 4 to 5 times higher than in adults, sig-
nificantly lower Bu-SE with oral Bu administration
when the dose range used was the same as originally
used in adults. Thus, the dosing regimen of 1 mg/kg
every 6 hours for 4 days was associated with very few
toxic adverse effects, however, it predisposed pediatric
patients to an increased risk for relapse and primary
graft failure [75,84,85]. Various mechanisms have
been proposed for this difference in clearance, that
is, altered intestinal drug absorption, increased hepatic
first pass clearance rate in younger children, and an
increased volume of distribution. These mechanisms
could contribute to the lower AUC values consistently
noted in children [94-99]. Further, Gibbs and col-
leagues [100] demonstrated that children younger
than 4 years appear to have a 2 to 4 times enhanced
ability to metabolize Bu in comparison with adults.
This higher clearance is probably (at least in part)
because of an increased formation of Bu/GSH conju-
gate in both the liver and upper intestinal wall mucosa,
which may contribute to a greatly enhanced clearance
of oral Bu, as an important mechanism by which
children metabolize Bu more efficiently than adults
[99,100].
Several studies suggested that dosing based on BSA
may be more appropriate to obtain an AUC closer to
adult values [84,96-99]. Vassal and colleagues [99]
proposed a dose of 600 mg/m2, to arrive at a similar
Bu-SE to the AUC values seen in adults, and similar
adverse effects profile as recorded with the more com-
monly used course dose of 16 mg/kg dose [99]. How-
ever, even with this approach, a wide interpatient
variability was noted, ranging from 3500 to 13,000
ng$h/mL (approximately 850-3300 mMol/min) [99].
The original dosing schedule of Bu administered at
1 mg/kg orally every 6 hours over 4 days was gradually
modified in children to improve the safety and efficacy
of drug delivery in response to the particularities
related to accelerated Bu clearance seen in pediatric
patients. Shaw and coworkers [101] suggested that
a single daily oral Bu dose (either 4 mg/kg or 600 mg/
m2) would be equivalent to divided doses and showed
similar pharmacokinetic data except to a predicted 4-
fold higher peak concentration. They suggested that
this would be more convenient without increasing the
risk of serious adverse effects. The once-daily dose de-
livery schedule yielded Bu plasma peak concentrations
reached approximately 2 hours after administration.
The drug was virtually completely eliminated at 24
hours in the majority of patients. Moreover, when the
AUC was used to calculate the Bu-SE, no significant
differences were found between younger and older
children. This contrasted with the 1 mg/kg divided
dosing schedule, which was associated with a signifi-
cantly lower Bu-SE in younger children [101,102].
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patient variability in children than in adults
[52,97,100-102]. Therefore, controlling Bu-SE in
children became even more important to avoid the
highly variable exposures that predispose to serious
adverse events, that is, graft rejection and leukemic
recurrence [75,84,93]. Targeting Bu to AUC values
between 900 and 1500 mMol/min optimized the
chance for engraftment and reduced the risk for severe
toxicity, similar to that seen in the adult population
[93,103]. Accepting that there is a continuous variation
in Bu clearance inversely correlated with weight in
children, Vassal, et al [93] recently proposed a refined
dosing schedule based on body weight for centers that
do not have access to PK monitoring. This group ad-
ministered i.v. Bu in combination with either Mel or
Cy in 55 patients on an every 6-hour schedule for 4
days, at 5 decrementing doses for a progressively
increasing bodyweight, on the presumption that a con-
tinuous decrease of Bu clearance requires a gradual
decrease in the dose administered. Doses ranging
from 1.2 mg/kg to 0.8 mg/kg were administered to
children weighing from less than 9 kg to more than
34 kg. The great majority of patients (91%) achieved
an AUC in the targeted range with low interpatient
variability. In this context, it may also be of interest
to note the retrospective comparison between TBI/
Cy and oral Bu/Cy in a matched pair analysis of pedi-
atric patients having allogeneic SCT for ALL from the
IBMTR [104]. This report strongly favored TBI/Cy
over oral Bu/Cy, mostly without PK-guidance, in ref-
erence to OS, DFS and TRM [104]. It is important to
note that, first, the introduction of i.v. Bu and then the
replacement of Cy with Flu in the i.v. Bu/Flu and i.v.
Bu/Flu/ATG regimens have contributed to drastically
reduced TRM and improved OS and DFS for adults
with AML/MDS and ALL [68,69,105]. Second, in pe-
diatric SCT the i.v. Bu has made it easier to accurately
utilize the TDM concept to achieve dosing accuracy
with consistent systemic exposure. More recent re-
ports also show improved OS and DFS for patients
receiving i.v. Bu-based conditioning therapy when
compared with historic oral Bu controls. Additionally,
Worth and colleagues [106] reported excellent 10-year
OS andDFS in high-risk pediatric patients with AML/
MDS and ALL. In particular, their engraftment rate of
.90% and a 10-year DFS of 60% in a subpopulation
of patients who received a single cord blood transplant
for advanced leukemia are encouraging. Finally, the
data of Russell et al. [105], utilizing their modified
Bu/Bu/Flu/ATG/TBI regimen in adults with ALL
(see below), together with the emerging concerns
about long-term sequelae of TBI in pediatric patients,
suggest that it may be time to reevaluate the purported
superiority of TBI/Cy with that of an i.v. Bu-based
conditioning regimen when optimized within the
realm of TDM for pediatric patients.CURRENT STATE-OF-THE-ARTAND FUTURE
DEVELOPMENTS WITH I.V. BU-BASED
CONDITIONING THERAPY
Available clinical results indicate, that the i.v.
Bu/Flu conditioning regimens are safe and effective,
and are being adopted as ‘‘standard of care’’ preparative
regimens for myelogenous diseases by many transplant
centers. Although no head-to-head comparison with
Bu/Cy2 exists, available retrospective data comparing
Bu/Flu with Bu/Cy2 suggest that Bu/Flu is indeed
safer and at least as cytoreductive as Bu/Cy2 for pa-
tients with hematologic malignancies undergoing
HSCT. Three retrospective studies performed in the
past few years compared i.v. Bu/Flu with Bu/Cy2
[71-73]. In 1 of them, Bredeson and colleagues [73] re-
ported a retrospective matched-pair analysis of 120 pa-
tients treated i.v. Bu/Flu plus ATG with 215 control
patients treated with oral Bu/Cy2. This analysis partly
confirmed the dramatic differences in treatment-re-
lated mortality (12% versus 34%, P\ .001) and grades
II-IV aGVHD (15% versus 34%) in patients treated
with i.v. Bu/Flu/ATG compared with those receiving
Bu/Cy2. However, they found a higher relapse rate
for patients receiving i.v. Bu/Flu/ATG, translating to
a similar os at 5 years (58% i.v. Bu/Flu/ATG and
51% Bu/Cy2), although the 100-day-, 1-year, and 3-
year survival rates were greater and reached near statis-
tical significance in patients treated with i.v. Bu/Flu/
ATG [73]. The effaced difference in outcomes be-
tween i.v. Bu/Flu/ATG and Bu/Cy2 regimens at 5
years is not entirely clear, presumably a cumulative re-
lapse rate for indolent diseases like multiple myeloma
(MM), CML, and some lymphomas may contribute,
as diseases like AML or MDS are less likely to recur
at 3 or more years after HSCT. It may be of impor-
tance to remember that the patients in this study had
a variety of hematologic malignancies. Therefore,
comparisons of different conditioning regimens may
benefit from being disease-specific to address whether
antitumor efficacy is the same for regimens used for
patients in different diagnostic subcategories. Further-
more, the described i.v. Bu/Flu/ATG program uses
ATG. including a dose delivered on the day of the graft
infusion, such that this cohort may mimic the out-
comes of a T cell-depleted transplant, where a higher
relapse rate is commonly observed. There was no indi-
cation that ATG was used in the oral Bu/Cy2 group.
A variant of the Bu/Flu/ATG regimen was ex-
plored recently by Russell and coworkers [105]. They
treated 64 adult patients with acute leukemia in first
or second remission with i.v. Bu/Flu and 400 cGy
TBI. This variant of their previously reported regimen
added TBI at 200 cGy given twice on days21 or day 0,
to enhance the antileukemic effect of the i.v. Bu/Flu/
ATG regimen. All patients engrafted with a treat-
ment-related mortality of only 3%, similar to the
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DFS at 3 years of 83% 6 6% for AML and 65% 6
10% for ALL was reported [105]. Although the num-
bers were limited, the results are encouraging, espe-
cially for ALL patients, as a recent large
retrospective analysis had shown only a modest 25%
OS after the TBI/Cy or (oral) Bu/Cy2 conditioning
regimens [107].
Bu/Flu conditioning has also been tested in the
context of unrelated umbilical cord blood transplanta-
tion (UCBT), both with the drugs given sequentially
and in the standard fixed-dose i.v. Bu/Flu (Bu 130
mg/m2/day and Flu 40 mg/m2/day  4 days) regimen,
as well as with PK-guided i.v. Bu delivery [108]. These
i.v. Bu/Flu variant regimens performed poorly in
patients receiving an UCBT; from 8 (of 10 total) pa-
tients who were evaluable for engraftment, and who
received a double cord transplant for myeloid
malignancies in CR, only 2 engrafted with donor
derived hematopoiesis. No ATG was administered in
this study, which could have contributed to an exces-
sive graft failure rate. These results are in agreement
with (unpublished) data from MDACC, where only
6 of 11 UCB recipients conditioned with PK-guided
i.v. Bu/Flu engrafted. However, the addition of
a low dose of TT, to the i.v. Bu/Flu regimen as re-
ported by Sanz and colleagues [109], demonstrates
that a modified i.v. Bu/Flu regimen could successfully
be used for UCBT. This group treated 73 patients
with hematologic malignancies (65 with acute leuke-
mia and MDS) with TT/Bu/Flu, and used ATG
with cyclosporine (CsA) and steroids as GVHD pro-
phylaxis. The (presumed) improved eradication of
host T cells by the addition of TT dramatically im-
proved engraftment. Only single cords were used in
this study and about 90% of the patients successfully
achieved engraftment [109]. The rate of grade II-IV
aGVHD was only 16% and day 1100 TRM was
14% [109]. Another approach was used by Russell
and coworkers [105], who utilized their i.v. Bu/Flu/
ATG regimen supplemented with 200 cGy TBI for
2 doses, with the radiation therapy given the day be-
fore umbilical cord blood graft infusion [105]. Using
also single unrelated cord blood grafts these investiga-
tors achieved engraftment in 12 of 12 evaluable pa-
tients before transplant day 30 ( J. Russell, personal
communication, November, 2008).Bu/Mel Conditioning Chemotherapy
Another approach to avoid the toxicity of adding
Cy to Bu conditioning while maintaining a high degree
of myeloablation was to replace Cy withMel, in a com-
bination to treat (primarily) lymphoid malignancies,
especially ALL, for which current conditioning
regimens provide disappointing results [108]. The
Bu/Mel has been evaluated both in the autologousand allogeneic stem cell transplant setting, in adults
and children [110-115]. These various regimens used
in single-arm phase II studies have provided promising
results, and controlled studies are warranted. For in-
stance, in an ongoing trial, Kebriaei and coworkers
[115] are evaluating once-daily i.v. Bu in combination
withMel (70 mg/m2 daily for 2 doses) for ALL and ad-
vanced high-grade lymphomas. Although this combi-
nation was well tolerated, disease control in the ALL
subpopulation was still too early to fully evaluate; how-
ever, in a cohort of 30 ALL patients the 1-year survival
was approximately 80% (P. Kebriaei, personal com-
munication, November, 2008). This combination reg-
imen appears at least as good as what would be
expected with TBI/Cy in a patient population with
an average age of about 35 years [105,107,115]. Fur-
thermore, Wall and coworkers [116] reported recently
on the use of Bu/Mel/ATG regimen as conditioning
for unrelated UCBT in pediatric patients. Again, the
regimen was well tolerated, engraftment of granulo-
cytes was achieved in 60% of patients by day 142
following a bone marrow transplant (BMT), and
a 1-year OS rate of 47%.
Bu—Alternative Nucleoside Analogs in
Pretransplant Conditioning
Clofarabine and nelarabine are newer purine ana-
logues, which, similar to Flu, are active in various
hematologic malignancies. Both drugs have been
recently granted FDA approval for treatment of
advanced ALL/lymphoma [117,118]. The immuno-
suppressive and engraftment promoting capability of
these nucleoside analogs remains unconfirmed,
although the molecular structure of clofarabine sug-
gests that it is likely to be at least comparable with
that of Flu. To improve the cytoreductive effect of
Bu/Flu regimen, i.v. Bu is being combined with clofar-
abine, in ongoing early trials [119]. Twenty-five
patients with advanced AML/MDS were treated at
MDACC with a combination of i.v. Bu/clofarabine
6 Flu. All evaluable patients engrafted uneventfully,
and when assessed approximately at 1 month and 3
months posttransplant the T cell chimerism appeared
to be at least as high as that achieved with the Bu/Flu
combination. Although it is too early to evaluate dis-
ease control, the preliminary data demonstrate the
potential of Clo to be used as an alternative to Flu in
combination with Bu in pretransplant conditioning
therapy.
Bu-Nucleoside Analog as a Platform for Future
Conditioning Regimens
i.v. Bu (6 pharmacokinetic monitoring) allows
precise drug delivery and control of systemic exposure,
to minimize adverse effects and optimize the antitu-
mor effect, and, in combination with Flu, represents
1 2 3, 4 5 6
Bu - Flu ± ATG          HSC     Post Tx
Clinical Laboratory/Translational
1. Pre – reduction/mobilization of malignant cells Molecular/mechanistic
2. PK – guided Bu delivery, Cellular (Resistance) ,
pharmacogenetic studies
3. Alternative Nucleoside – e.g. clofarabine
4. Small molecules, e.g. methylation changes
5. Specialty engineered Graft
6. Post Transplant Intervention,  pharmacologic (e.g. Cy, Pentostatin), 
immunomodulatory e.g. anti-tumor vaccines
“Conditioning Platform”
Figure 1. Potential peritransplant interventions added to the i.v. Bu/Flu conditioning regimen for hematopoietic stem cell transplantation.
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consideration of i.v. BuFlu as an emerging platform
technology can be anticipated to lead into investiga-
tion of novel strategies to further improve outcomes
of transplantation, as exemplified in Figure 1. First,
improvement of the cytoreductive effect could be po-
tentially accomplished by the addition of mobilizing
agents, such as plerixafor, based on the hypothesis
that leukemic cells are more sensitive to chemotherapy
when dissociated from the marrow stroma. Second,
demethylating agents are of importance for the devel-
opment of drug resistance in myelogenous leukemia
(MDS, AML). By adding such agents like azacitidine
or decitabine to manipulate the methylation status of
malignant cell DNA, an increased sensitivity of the
malignant cells could be achieved. Third, the addition
of other chemotherapeutic agents, such as TT or low-
dose TBI, might enhance antileukemic activity for
lymphoid malignancies, and as well as promote en-
graftment after UCBT. Fourth, the reduced toxicity
of the conditioning regimen now safely allows the
use of posttransplant immunomodulation (ie, Cy or
pentostatin) to reduce the incidence of GVHD and
allow the use cellular therapy after transplant.
In conclusion, much has been accomplished over
the past 30 years in conditioning regimens for
HSCT. i.v. Bu in combination with Flu for patients
with myelogenous malignancies in CR1 is associated
with .80% long-term survival because of improve-
ment in safety of chemotherapy administration and
decreased TRM [68,69,105]. Available data proves
that i.v. Bu/Flu (6ATG) is a safer and at least as effec-
tive preparative regimen compared with either of the
Bu/Cy2 variants or TBI/Cy, although there are no
head-on comparisons available. The Bu/Flu regimen
represents an important step forward in conditioning
for HSCT, especially for myelogenous malignancies,and can conceptually be considered as a platform for
developing improved preparative regimens for lym-
phoid malignancies, alternative donor transplantation,
as well as for other subgroups of high-risk patients for
which outcomes are largely unsatisfactory using the
available conditioning regimens.ACKNOWLEDGMENTS
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